. Author manuscript; available in PMC: 2024 May 2.

Published in final edited form as: Cell Metab. 2023 Apr 20;35(5):855–874.e5. doi: 10.1016/j.cmet.2023.03.022

Table 2.

Clinical features of EAE after therapeutical treatment of Bezafibrate and Fingolimod

Group	# Sick/total (incidence)	Maximum clinical score	Cumulative disease index	Mean weight on peak day
Vehicle	12/12 (100%)	2.4 ± 0.2	26.0 ± 1.8	19.8 ± 0.5
Bezafibrate	11/11 (100%)	2.2 ± 0.2	23.1 ± 2.1	20.0 ± 0.5
Fingolimod	11/11 (100%)	1.8 ± 0.2	17.1 ± 1.9^**	20.1 ± 0.4
Bezafibrate + Fingolimod	11/11 (100%)	1.6 ± 0.1^*	12.7 ± 1.8^***	20.0 ± 0.5

Values shown are mean ± SEM; n =12 or 11 per group.

p< 0.05,

^**

p< 0.01,

^***

p< 0.001 vs. vehicle group.

Cumulative disease index: sum of clinical score of the entire period